Aeglea BioTherapeutics, Inc. (AGLE) financial statements (2020 and earlier)

Company profile

Business Address 805 LAS CIMAS PARKWAY
AUSTIN, TX 78746
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:72755064
Cash and cash equivalents19221348
Short-term investments53523716
Other undisclosed cash, cash equivalents, and short-term investments (0)0(0)
Receivables  31
Other undisclosed current assets3222
Total current assets:75775566
Noncurrent Assets
Operating lease, right-of-use asset5
Property, plant and equipment2111
Restricted cash and investments2   
Other noncurrent assets0000
Total noncurrent assets:9111
TOTAL ASSETS:83785667
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8432
Accounts payable3100
Accrued liabilities1111
Employee-related liabilities3321
Debt0   
Deferred revenue and credits00
Other undisclosed current liabilities10632
Total current liabilities:181064
Noncurrent Liabilities
Long-term debt and lease obligation5   
Operating lease, liability5
Liabilities, other than long-term debt0000
Other liabilities0000
Total noncurrent liabilities:5000
Total liabilities:231064
Stockholders' equity
Stockholders' equity attributable to parent60675063
Common stock0000
Additional paid in capital255184123108
Accumulated other comprehensive income (loss)0(0)(0)(0)
Accumulated deficit(195)(117)(73)(45)
Total stockholders' equity:60675063
TOTAL LIABILITIES AND EQUITY:83785667

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net55
Gross profit: 455
Operating expenses(80)(49)(33)(27)
Operating loss:(80)(45)(28)(22)
Nonoperating income2100
Investment income, nonoperating2100
Other nonoperating expense(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(78)(44)(27)(22)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(78)(44)(27)(22)
Comprehensive loss:(78)(44)(27)(22)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)(0)
Comprehensive loss, net of tax, attributable to parent:(78)(44)(27)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: